Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1020 + Albumin-bound Paclitaxel in Advanced Pancreatic Cancer
NCT04814485Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
famitinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04814485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814485.